TASE:ITMR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Itamar Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ITMR is more volatile than 75% of IL stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ITMR's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of IL stocks.


Market Performance


7 Day Return

-4.5%

ITMR

-9.1%

IL Medical Equipment

-2.0%

IL Market


1 Year Return

53.1%

ITMR

35.0%

IL Medical Equipment

-0.5%

IL Market

Return vs Industry: ITMR exceeded the IL Medical Equipment industry which returned 35% over the past year.

Return vs Market: ITMR exceeded the IL Market which returned -0.5% over the past year.


Shareholder returns

ITMRIndustryMarket
7 Day-4.5%-9.1%-2.0%
30 Day-6.5%2.2%-1.0%
90 Day16.8%23.0%5.1%
1 Year53.1%53.1%35.2%35.0%1.8%-0.5%
3 Year159.9%159.9%54.7%54.1%27.9%17.2%
5 Year89.1%89.1%-55.3%-55.4%73.9%49.9%

Long-Term Price Volatility Vs. Market

How volatile is Itamar Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Itamar Medical undervalued compared to its fair value and its price relative to the market?

6.9x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ITMR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ITMR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ITMR is unprofitable, so we can't compare its PE Ratio to the IL Medical Equipment industry average.

PE vs Market: ITMR is unprofitable, so we can't compare its PE Ratio to the IL market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ITMR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ITMR is overvalued based on its PB Ratio (6.9x) compared to the IL Medical Equipment industry average (2.3x).


Next Steps

Future Growth

How is Itamar Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

57.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ITMR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: ITMR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ITMR's is expected to become profitable in the next 3 years.

Revenue vs Market: ITMR's revenue (24.8% per year) is forecast to grow faster than the IL market (8% per year).

High Growth Revenue: ITMR's revenue (24.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ITMR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Itamar Medical performed over the past 5 years?

9.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ITMR is currently unprofitable.

Growing Profit Margin: ITMR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ITMR is unprofitable, but has reduced losses over the past 5 years at a rate of 9.6% per year.

Accelerating Growth: Unable to compare ITMR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ITMR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.1%).


Return on Equity

High ROE: ITMR has a negative Return on Equity (-19.55%), as it is currently unprofitable.


Next Steps

Financial Health

How is Itamar Medical's financial position?


Financial Position Analysis

Short Term Liabilities: ITMR's short term assets ($57.9M) exceed its short term liabilities ($15.4M).

Long Term Liabilities: ITMR's short term assets ($57.9M) exceed its long term liabilities ($2.6M).


Debt to Equity History and Analysis

Debt Level: ITMR's debt to equity ratio (10.9%) is considered satisfactory.

Reducing Debt: ITMR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ITMR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ITMR has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 5.4% each year.


Next Steps

Dividend

What is Itamar Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ITMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ITMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ITMR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ITMR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ITMR's dividend in 3 years as they are not forecast to pay a notable one for the IL market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Gilad Glick (47 yo)

7.58yrs

Tenure

US$982,000

Compensation

Mr. Gilad Glick has been the Chief Executive Officer and President of Itamar Medical Ltd., since July 1, 2013 and serves as its Acting Vice President of Marketing and Sales. He serves as an Acting Presiden...


CEO Compensation Analysis

Compensation vs Market: Gilad's total compensation ($USD982.00K) is above average for companies of similar size in the IL market ($USD667.49K).

Compensation vs Earnings: Gilad's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Gilad Glick
President7.58yrsUS$982.00k0.079%
$ 1.0m
Shy Basson
CFO & COO of U.S.3.75yrsUS$538.00k0%
$ 0
Itay Kariv
Vice President of R&D and Technologyno dataUS$309.00k0%
$ 0
Eilon Livne
Vice President of Sales & Channels Development EMEA1.08yrsUS$281.00k0%
$ 0
Giora Yaron
Founder & Chairman of the Board5.08yrsUS$94.06k5.97%
$ 76.8m
Peretz Lavie
no datano datano data
Daniel Goor
no datano datano data
Dan Shlezak
Vice President of Operations & Engineering1.08yrsno datano data
Gil Ashkenazi
Legal Counselno datano datano data
Daphna Triwaks
Head of Public Relationsno datano datano data
Sidney Ashmore
Vice President of Marketingno datano datano data
Jeff Schmidt
Senior Vice President of North American Sales1.08yrsno datano data

1.1yrs

Average Tenure

55yo

Average Age

Experienced Management: ITMR's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Giora Yaron
Founder & Chairman of the Board5.08yrsUS$94.06k5.97%
$ 76.8m
Yaffa Krindel
Independent External Director5.08yrsUS$8.28k0.034%
$ 439.9k
Jonathan Kolber
Independent Director5.17yrsUS$6.76kno data
Ilan Biran
Independent Director7.75yrsUS$19.75k0.020%
$ 254.9k
Sami Totah
Independent Director5.17yrsUS$6.76kno data
Zipora Ozer-Armon
Independent External Director5.08yrsUS$7.79k0%
$ 0
Amir Lerman
Member of Advisory Boardno datano datano data
Peter Gantz
Member of Advisory Boardno datano datano data
Michael Shechter
Member of Advisory Boardno datano datano data
Peter Collins
Member of Advisory Boardno datano datano data
Kirk Garratt
Member of Advisory Boardno datano datano data
Binoy Singh
Member of Advisory Boardno datano datano data

5.1yrs

Average Tenure

63.5yo

Average Age

Experienced Board: ITMR's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.4%.


Top Shareholders

Company Information

Itamar Medical Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Itamar Medical Ltd.
  • Ticker: ITMR
  • Exchange: TASE
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ₪1.287b
  • Shares outstanding: 505.15m
  • Website: https://www.itamar-medical.com

Number of Employees


Location

  • Itamar Medical Ltd.
  • 9 Halamish Street
  • North Industrial Zone
  • Caesarea
  • 3088900
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ITMRTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSMar 2007
ITMM.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2007
ITMRNasdaqCM (Nasdaq Capital Market)SPONSORED ADSUSUSDFeb 2019

Biography

Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market. The company offers medical devices based on Peripheral Arte...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/02/25 17:15
End of Day Share Price2021/02/25 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.